Catalyst Pharmaceuticals (CPRX) Expected to Announce Earnings on Wednesday

Catalyst Pharmaceuticals (NASDAQ:CPRX - Get Free Report) is expected to be releasing its earnings data after the market closes on Wednesday, February 26th. Analysts expect Catalyst Pharmaceuticals to post earnings of $0.32 per share and revenue of $134.20 million for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ:CPRX traded down $0.42 during midday trading on Friday, hitting $21.63. 918,453 shares of the stock were exchanged, compared to its average volume of 1,235,675. The stock has a market capitalization of $2.58 billion, a price-to-earnings ratio of 18.33, a P/E/G ratio of 3.38 and a beta of 0.80. The business's 50-day moving average price is $22.25 and its 200 day moving average price is $21.25. Catalyst Pharmaceuticals has a 12 month low of $13.49 and a 12 month high of $24.64.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, Director Molly Harper sold 17,500 shares of the firm's stock in a transaction dated Wednesday, November 27th. The stock was sold at an average price of $22.00, for a total value of $385,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Steve Miller sold 50,000 shares of the firm's stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the completion of the transaction, the insider now owns 686,996 shares of the company's stock, valued at approximately $15,065,822.28. This represents a 6.78 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 79,500 shares of company stock worth $1,754,140 in the last quarter. 11.00% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. Robert W. Baird assumed coverage on Catalyst Pharmaceuticals in a research note on Tuesday, February 4th. They issued an "outperform" rating and a $28.00 price target on the stock. Truist Financial increased their price target on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a "buy" rating in a research report on Monday, November 11th. Baird R W raised Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Monday, February 3rd. StockNews.com lowered Catalyst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, January 11th. Finally, Stephens initiated coverage on Catalyst Pharmaceuticals in a research report on Monday, November 18th. They issued an "overweight" rating and a $35.00 price target for the company. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals has a consensus rating of "Buy" and a consensus price target of $32.25.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.